Click' Login' then 'Don't have an Account ' and join $$Lounge for free

Lexaria Corp CSE:LXX OTC:LXRP

More
3 months 9 hours ago #120365 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Another patent award coming, news out this morning

KELOWNA, BC / ACCESSWIRE / March 22, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing for "composition of matter" claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids. This is a significant addition to Lexaria's existing manufacturing "method of use" patent rights previously granted.

"This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology," said John Docherty, President. "This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties."

Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,802, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." As has been Lexaria's experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less.

Lexaria has additional patent applications that remain within the USPTO process, of both the composition of matter and process varieties. Lexaria will continue to develop and strengthen its patent portfolio in the USA, Canada, and internationally and expects further patent awards this year. As its patent portfolio increases, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Lexaria's patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient ("API") substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.

Please Log in or Create an account to join the conversation.

  • lynnsa10
  • lynnsa10's Avatar
  • Away
  • Elite Member
  • Elite Member
More
3 months 2 days ago #120357 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Sounds like different process that LXX, absorption through the blood stream compared to LXX through digestion.

News out this morning

Lexaria Files New Patent Application for Enhanced Transdermal Delivery System

KELOWNA, BC / ACCESSWIRE / March 20, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office (''USPTO'') for use of DehydraTECHTM to improve the speed and quantity of absorption of active pharmaceutical ingredients (''API'') through the skin.

The patent application follows the recently announced successful laboratory evaluation of DehydraTECHTM in the transdermal delivery of cannabidiol (''CBD'') that showed as much as a 225% increase in CBD permeability compared to control formulations tested with leading commercial penetration enhancers; and almost a 1,900% increase in CBD permeability compared to a control formulation that was devoid of both the DehydraTECHTM technology or any commercial penetration enhancers. The original research protocols were overseen by Lexaria President John Docherty and represent a unique, new and improved method of transdermal delivery for cannabinoids and potentially many other active ingredients.

In the patent application, Lexaria has applied for patent protection for the delivery of all of the active ingredient classes already identified in its other issued and pending patent applications including cannabinoids, terpenes and terpenoids, NSAIDs, vitamins, nicotine and phosphodiesterase inhibitors, as well as a broad range of additional active ingredients commonly found in topical products today that may benefit from enhanced skin permeability performance in concert with the DehydraTECHTM technology.

The Company believes that its DehydraTECHTM technology could drive significant innovation and improvement for the delivery of active ingredients through topical products, transdermal patches, cosmetics and many other skin-oriented consumer product formats. Lexaria will initiate third-party licensing discussions for this new transdermal application of DehyrdaTECHTM as soon as possible.

Lexaria's patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120315 by CIMA
CIMA replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
finance.yahoo.com/news/ctt-pharmaceutica...-ctth-154230507.html

“This newly issued patent is the most valuable and difficult to obtain relative to the other four patents that the Company has been previously issued,” said Dr. Pankaj Modi, CEO of CTTH. “The claims allowed are so broad that virtually any entity in Canada that comes to market with a strip, wafer, tablet, or gum that has any active therapeutic molecule such as cannabinoids or opioids will be infringing upon our patent. The nanonization of cannabinoids and opioids through our Fast Dissolving Oral Thin Film sub-lingual wafers will provide the Company and its licensed Canadian distribution partner the opportunity to dominate and monopolize this industry in Canada. This patent also allows for the introduction of opioid reduction formulations whereby 10% to 25% of the opioid analgesics dose can be combined with 75% to 90% cannabinoids like THC and/or CBD which would reduce opioid consumption and overdosing possibilities and improve the safety profile of daily multiple doses of pain medications.”

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120309 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
another interesting tidbit in the Post

The Financial Post reports in its Thursday edition that major alcohol companies will likely see sales squeezed by legal cannabis in the coming years, according to research firm CFRA Research. The Post's Mark Rendell writes that CFRA analyst Joe Agnese says, "Due to shared usage occasions, we view the legalization of cannabis as a threat to alcohol industry consumption growth." Mr. Agnese cites AnheuserBusch InBev, The Boston Beer Company and Brown-Forman, best known for Jack Daniels Tennessee Whiskey, as companies that could see a decline in product consumption. Mr. Agnese says: ""When I consider the use indications of the alcohol industry -- when it's consumed, who consumes it, that type of environment -- alcohol overlaps significantly with cannabis, whereas something like tobacco doesn't. While you are going to see a big shift from the illegal (cannabis) market to the legal market, you're also going to have a lot of alcohol consumers who don't consider cannabis, because it's illegal, moving over to consuming cannabis, especially with the development of closer alternatives such as infused beverages. ... Canada's going to be just a wonderful test market for the U.S. to see how it all plays out."

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120294 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Interesting news today

The Financial Post reports in its Wednesday edition that Canada fell to a surprise second place behind the United Kingdom in 2016 legal cannabis production. The Post's Mark Rendell writes that according to a U.N.-backed report, the U.K. produced 95,000 kilograms of legal marijuana in 2016, compared with Canada's 80,732 kilograms. The U.K. exported 2,100 kilograms, 67.7 per cent of the global total; Canada moved less the 100 kilograms across borders in 2016. The U.K.'s finish at the top of the pile is unexpected, given the country has no legal medical cannabis framework. It does, however, allow the cannabis-based product Sativex, which is produced by GW Pharmaceuticals, for multiple sclerosis treatment.

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120293 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
CIMA, seems the CTT patent is a lot different than LXX, to do with wafers. I looked at their clinical study info and it appears that it does not work as well as vaporizing. I don't get what big advantage they have other than wafers might be preferred over smoking, but if it is not as good as vaporizing, what is the big deal??

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120292 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
American smokers are stubbing out their cigarettes. Data from the Centers for Disease Control and Prevention (CDC) show that the proportion of the adult American population that has smoked at least 100 cigarettes during their lifetimes stood at 15.5 percent in 2016, down from 20.9 percent in 2005 ( nnw.fm/J6dQp ). Of course, quitting smoking does not always mean saying no to nicotine. The stimulant, credited with some health benefits, is highly addictive. As a result, alternative delivery biotechnologies for nicotine have become a recent R&D focus for cigarette manufacturers and other companies, including Lexaria Bioscience Corp.

www.networknewswire.com/smokers-light-le...s-take-center-stage/

Please Log in or Create an account to join the conversation.

More
3 months 2 weeks ago #120261 by CIMA
CIMA replied the topic: Lexaria Corp CSE:LXX OTC:LXRP

Please Log in or Create an account to join the conversation.

More
3 months 4 weeks ago - 3 months 4 weeks ago #120186 by ron
ron replied the topic: Lexaria Corp CSE:LXX OTC:LXRP

GoldnBoy wrote: Maybe you got lucky for some, I see good old Jitney sold 1,000 shares, just 5 seconds before market close to knock the stock down 10 cents. It is pathetic regulators let this nonsense continue over and over again


can they hold it down on a good news,don't think so,they're going to get burn one of these days.
Last Edit: 3 months 4 weeks ago by ron.

Please Log in or Create an account to join the conversation.

More
4 months 1 hour ago #120185 by GoldnBoy
GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Maybe you got lucky for some, I see good old Jitney sold 1,000 shares, just 5 seconds before market close to knock the stock down 10 cents. It is pathetic regulators let this nonsense continue over and over again

Please Log in or Create an account to join the conversation.

More
4 months 5 hours ago #120184 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Got a bid in, hope it goes a bit lower

Please Log in or Create an account to join the conversation.

More
4 months 8 hours ago #120182 by GoldnBoy
GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
New article on Lexaria here
www.b-tv.com/lexaria-bioscience-feature-ep-324/

Lexaria Bioscience Corp. evolved into its current form in 2014 upon controlling acquisition of the former company where Lexaria’s DehydraTECH™ technology originated. Since then, Lexaria has quickly emerged as a global leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products while also working to expand the applicability of its technology, within and beyond the cannabinoid sector, through its out-licensing business model for cannabinoids and other bioactive molecules named in its patent portfolio (NSAIDs, nicotine, vitamins and more). Lexaria produces industry-leading research to support its novel delivery method.

Please Log in or Create an account to join the conversation.

Time to create page: 0.195 seconds

Login Form